Literature DB >> 8038108

Cyclic GMP and regulation of cyclic nucleotide hydrolysis.

W K Sonnenburg1, J A Beavo.   

Abstract

Several of the different PDE isozyme families have the ability in vitro to hydrolyze cGMP. In particular they include the CaM-dependent PDEs, the cGMP-stimulated PDEs, and the cGMP binding, cGMP-specific PDEs. Existing evidence suggests or demonstrates that in different cell types, each of these can be important determinants for the control of cGMP steady-state levels. Each of these enzymes is differentially expressed and regulated; moreover, the amount of the enzyme expressed and the mode of regulation determine to a large extent the rate of rise, maximal level, rate of fall, and duration of the cGMP signal in the cell. In addition to enzymes that function to degrade cGMP at least two also are regulated by cGMP both in vitro and in the intact cell. The cGMP-stimulated PDE has the ability to decrease cAMP levels in response to cGMP and the cGMP-inhibited PDE can increase cAMP levels in response to cGMP. We are just beginning to define how many different isozymes of PDE exist in mammalian tissues, where they are located, and how they are regulated. Selective inhibitors to each are being developed and studies designed to define structural features that determine the mechanisms of action and regulation of the PDEs have been initiated. It is expected that in the next few years more PDEs will be discovered and the functions of the new an existing ones with be more clearly defined.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8038108     DOI: 10.1016/s1054-3589(08)60052-6

Source DB:  PubMed          Journal:  Adv Pharmacol        ISSN: 1054-3589


  9 in total

1.  Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition.

Authors:  Heather N Tinsley; Bernard D Gary; Jose Thaiparambil; Nan Li; Wenyan Lu; Yonghe Li; Yulia Y Maxuitenko; Adam B Keeton; Gary A Piazza
Journal:  Cancer Prev Res (Phila)       Date:  2010-09-28

Review 2.  Cellular and molecular mechanisms regulating vascular tone. Part 2: regulatory mechanisms modulating Ca2+ mobilization and/or myofilament Ca2+ sensitivity in vascular smooth muscle cells.

Authors:  Takashi Akata
Journal:  J Anesth       Date:  2007-05-30       Impact factor: 2.078

3.  The subtype-2 (AT2) angiotensin receptor regulates renal cyclic guanosine 3', 5'-monophosphate and AT1 receptor-mediated prostaglandin E2 production in conscious rats.

Authors:  H M Siragy; R M Carey
Journal:  J Clin Invest       Date:  1996-04-15       Impact factor: 14.808

4.  Effects of cyclic GMP elevation on isoprenaline-induced increase in cyclic AMP and relaxation in rat aortic smooth muscle: role of phosphodiesterase 3.

Authors:  E Delpy; H Coste; A C Gouville
Journal:  Br J Pharmacol       Date:  1996-10       Impact factor: 8.739

Review 5.  New NSAID targets and derivatives for colorectal cancer chemoprevention.

Authors:  Heather N Tinsley; William E Grizzle; Ashraf Abadi; Adam Keeton; Bing Zhu; Yaguang Xi; Gary A Piazza
Journal:  Recent Results Cancer Res       Date:  2013

6.  On the genesis of myocardial ischemia.

Authors:  K Sroka
Journal:  Z Kardiol       Date:  2004-10

7.  Nitric oxide, an enteric nonadrenergic-noncholinergic relaxant transmitter: evidence using phosphodiesterase V and nitric oxide synthase inhibition.

Authors:  S J Williams; M E Parsons
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

8.  Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A.

Authors:  L Fawcett; R Baxendale; P Stacey; C McGrouther; I Harrow; S Soderling; J Hetman; J A Beavo; S C Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

Review 9.  Role of Nitric Oxide in the Cardiovascular and Renal Systems.

Authors:  Ashfaq Ahmad; Sara K Dempsey; Zdravka Daneva; Maleeha Azam; Ningjun Li; Pin-Lan Li; Joseph K Ritter
Journal:  Int J Mol Sci       Date:  2018-09-03       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.